literature

HIV mutation literature information.

Decline in CD4 T lymphocytes with monotherapy bridging strategy for non-adherent adolescents living with HIV infection: Results of the IMPAACT P1094 randomized trial.

PMID: 28604824 2017 PloS one

Introduction: Once the M184V mutation develops, no additional mutations occur with further use of 3TC or FTC monotherapy.

Introduction: The rationale for this strategy is as follows: 1) 3TC or FTC are components of the nucleoside/nucleotide reverse transcriptase inhibitor (NRTI) backbone of most first line cART regimens, 2) 3TC and FTC have minimal side effects, 3) the M184V resistance mutation, resulting in high-level drug resistance to both 3TC and FTC, develops rapidly in the setting of nonadherence and is present in many treatment-experienced children and adolescents with PA-HIV, 4) the M184V resistant mutation reduces viral fitness, and has been associated with a reduction in viral load of approximately 0.5 log10 c/mL, and 5) it does not confer significant cross-resistance to other

Multimethod Longitudinal HIV Drug Resistance Analysis in Antiretroviral-Therapy-Naive Patients.

PMID: 28659324 2017 Journal of clinical microbiology

Abstract: ART-naive HIV-1-infected patients from Cameroon were subjected to a multimethod HIVDR analysis using amplification-refractory mutation system (ARMS)-PCR, Sanger sequencing, and longitudinal next-generation sequencing (NGS) to determine their profiles for the mutations K103N, Y181C, K65R, M184V, and T215F/Y.

HIV drug resistance in HIV positive individuals under antiretroviral treatment in Shandong Province, China.

PMID: 28750025 2017 PloS one

Abstract: M184V was the most frequently found point mutation, conferring resistance to the nucleoside reverse transcriptase inhibitor, while Y181C, G190A, K103N and V179D/E/F were the most frequent point mutations conferring resistance to the non-nucleoside reverse transcriptase inhibitor.

Result: We found that M184V and Y181C were also the most frequent point mutations in these patients.

Result: We found that M184V was the most frequent point mutation conferring resistance against NRTIs, whereas Y181C, G190A

High level of HIV-1 drug resistance mutations in patients with unsuppressed viral loads in rural northern South Africa.

PMID: 28750647 2017 AIDS research and therapy

Abstract: The most common DRMs were; M184V (51.7%), K103N (50%), V106M (20.6%), D67N (13.3%), K65R (12%).

Result: Exceptionally, the M184V mutation prevalence in rural Limpopo was more closely related to urban Pretoria (51.7% vs.

Result: The most dominant DRM against the reverse transcriptase inhibitors (RTI), were M184V (51.7%), K103N (50%), V106AM (20.6%), G190A (13.8%), D67N (13.8%),

Comparison between next-generation and Sanger-based sequencing for the detection of transmitted drug-resistance mutations among recently infected HIV-1 patients in Israel, 2000-2014.

PMID: 28799325 2017 Journal of the International AIDS Society

Result: M184V (identified as minor variant in two patients) and T215S were the only highly prevalent NGS and SBS NRTI TDRM identified.

Table: M184V

Discussion: M184V, frequently observed in patients failing therapy, which is regarded as a mutation that reduces viral fitness more than any other NRTI mutation, may wane over time, likely as a consequence of reversion to the wild-type sequence.

Week 48 resistance analysis of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF versus Atazanavir + Ritonavir + Emtricitabine/Tenofovir DF in HIV-1 infected women (WAVES study GS-US-236-0128).

PMID: 28891788 2017 HIV clinical trials

Abstract: A62V, V90I, K103N, or E138A/G/K/Q; 68-82%) demonstrated virologic suppression at week 48, with no resistance development except for one patient with M184V and pre-existing K103N in the ATV + RTV + FTC/TDF group.

Abstract: Emergent resistance was rare (0% EVG/COBI/FTC/TDF; 1% ATV + RTV + FTC/TDF - 3 with M184V/I in RT).

Result: All 3 participants developed M184V/I in RT.

Community Based Antiretroviral Treatment in Rural Zimbabwe.

PMID: 28899102 2017 AIDS research and human retroviruses

Abstract: Seven participants had sequence data available, and five had drug resistance mutations, K65R, T69N, K101E, K103N, Y181C/I, M184V, and G190A.

Kinetics of Archived M184V Mutation in Treatment-Experienced Virally Suppressed HIV-Infected Patients.

PMID: 28961903 2017 The Journal of antimicrobial chemotherapy

Abstract: CONCLUSIONS: These findings help to alleviate concern that EFdA may not be active against viruses that contain both the M184I/V and E138K substitutions in RT.

Abstract: Cell culture selections with either EFdA or lamivudine using both subtype B and non-B clinical isolates selected the M184I/V substitutions in reverse transcriptase (RT).

Abstract: In other clinical trials that evaluated rilpivirine together with emtricitabine in first-line therapy, the emergence of both the M184I/V and E138K mutations in RT was demonstrated.

Rates of virological suppression and drug resistance in adult HIV-1-positive patients attending primary healthcare facilities in KwaZulu-Natal, South Africa.

PMID: 28981637 2017 The Journal of antimicrobial chemotherapy

Abstract: DRMs were detected in 89% of 123 specimens with VF, including M184I/V, K103N/S, K65N/R, V106A/M and Y181C.

Antiretroviral Drug Resistance Mutations among HIV Treatment Failure Patients in Tehran, Iran.

PMID: 29026792 2017 Iranian journal of public health

Abstract: The analysis of reverse transcriptase showed M184V (68.9%), T215YISF (44.8%), K103N (27.6%) and the analysis results of protease revealed G73SC (13.8%) and I47VA (6.9%).

Result: The most common mutation seen for the NRTIs was M184V and for the NNRTIs was K103N.

Table:

Browser Board

Co-occurred Entities

Filtrator